Serine-deficiency disorders comprise a new group of neurometabolic diseases and are caused by defects in the biosynthesis of the amino acid L-serine. In contrast to most neurometabolic disorders, serine-deficiency disorders are potentially treatable. Furthermore, the severe neurological symptoms observed in patients underscore the important roles of the serine biosynthetic pathway in brain tissue. An overview of the patients with serine-deficiency disorders reported to date, the biochemical findings and the results of treatment with amino acids is presented. Recent findings L-Serine biosynthesis plays an important role in multiple cellular reactions, particularly in the brain, as L-serine is a precursor of important metabolites such as nucleotides, phospholipids and the neurotransmitters glycine and D-serine. Disturbances of serine-glycine metabolism in relation to N-methyl-D-aspartatereceptor activation are supposed to play a role in psychiatric disease as well. Recent findings concerning these roles of Lserine-derived phospholipids and neurotransmitters are presented. Summary Congenital microcephaly, seizures and severe psychomotor retardation are symptoms of serine deficiency and can be treated with supplementation of L-serine, sometimes combined with glycine. The symptoms observed in serine deficiency confirm that L-serine and L-serine-derived metabolites play important roles in the central nervous system.
Introduction
Disorders of amino acid catabolism are among the most frequent inborn errors in humans, and have been recognized for many years. Their clinical phenotypes are variable, but are often accompanied by extensive neurological dysfunction. Patients affected by these disorders can suffer either from an acute encephalopathy, for example glycine encephalopathy (or nonketotic hyperglycinemia), or develop progressive mental retardation, illustrated by the natural history of untreated phenylketonuria. The hallmark of the biochemical diagnosis of these aminoacidopathies is the detection of characteristic metabolites accumulating in body fluids. Recently, the first patients with a defect in the biosynthesis of the amino acid L-serine, one of the socalled non-essential amino acids [1], were reported, together with the details of the effects of L-serine supplementation. These patients also suffered from severe neurological symptoms and were diagnosed not by the accumulation of a metabolite, but rather from the deficiency of serine in plasma and cerebrospinal fluid (CSF).
In this review, we first discuss the two serine-deficiency syndromes know to date, namely 3-phosphoglycerate dehydrogenase (3-PGDH) deficiency and 3-phosphoserine phosphatase (3-PSP) deficiency; thereafter, we discuss in more detail some of the functions of L-serine biosynthetic and the L-serine catabolic pathways in the central nervous system.
3-Phosphoglycerate dehydrogenase deficiency
This disorder was first reported by Jaeken et al. [1] in 1996. These authors reported two brothers with congenital microcephaly, severe psychomotor retardation and intractable seizures. Analysis of amino acids in plasma and CSF showed very low concentrations of the amino acids serine and glycine. The biochemical defect affects the first enzymatic step in the serine biosynthetic pathway (Fig. 1) . Since the first publication on 3-PGDH deficiency, only a limited number of patients have been reported in the literature [2-4,5 . ]. This may indicate that it is a very rare disorder indeed, or that the disorder is possibly underdiagnosed. The detection of low values of amino acids in CSF and plasma requires special attention; such features are easily overlooked because, by tradition, the biochemical diagnosis of inborn errors is based on the detection of elevated concentrations. Another confounding factor may be the fact that for many inborn errors of metabolism, plasma and urine are used for first-line investigations: urine is not informative for diagnosing serine-deficiency disorders, and plasma can only be used for reliable testing after an overnight fast.
A neurological presentation predominates in the clinical phenotype; in the majority of patients, the symptoms apparently started before birth as they were born with congenital microcephaly. Severe psychomotor retardation develops in the first months of life, and this is followed by the onset of seizures. Different patterns of clinical seizures were observed. Seizures either started as generalized tonic clonic seizures or as flexor spasms with West syndrome. In older patients, diagnosed at ages 5-9 years, different types of seizures were observed and consisted of tonic, atonic and myoclonic seizures as well as absences. In some patients, bursts of inappropriate laughing suggested that gelastic seizures were also present [6].
Electroencephalograms of patients with 3-PGDH showed a pattern of either hypsarrhythmia or severe multifocal epileptic abnormalities with poor background activity. Other neurological abnormalities included hyperexcitability, generalized hypertonia, spastic quadriplegia and nystagmus. In some patients, adducted thumbs, cataract, hypogonadism and megaloblastic anemia were present as additional clinical features [6] . The clinical and biochemical characteristics of reported patients with 3-PGDH deficiency are summarised in Table 1. In the patients diagnosed after the first year of life, psychomotor development was almost absent; such patients were severely handicapped and unable to sit, produced only consonant sounds and had severe feeding difficulties. In the first report [7] on characteristic magnetic resonance imaging (MRI) in patients (four) with 3-PDGH deficiency, before and during treatment, cranial MRI of patients diagnosed at ages 10 months to 7 years showed severe attenuation of the white-matter volume in combination with hypomyelination. These MRI findings were not observed in a patient diagnosed at 2 months of age and therefore are likely to have developed over time in the first year of life.
Diagnostic biochemical tests
Low concentrations of the amino acid serine and, to a variable degree, of glycine are the biochemical hallmark of the disease. In plasma, the abnormalities are only present in the fasted state, because of interference of the amino acids absorbed from the diet. In the postprandial state, normal plasma serine and glycine concentrations can be found. The biochemical abnormalities are more pronounced in CSF and are unrelated to meals. Therefore CSF amino acid analysis is preferable over plasma analysis. Analysis of amino acids in urine is not informative in 3-PGDH deficiency: normal excretion of serine and glycine is present. Besides deficiencies of CSF serine and glycine, low concentrations of 5-methyltetrahydrofolate have also been observed [2] . Because of a reported association between low CSF folates and deficiencies of the neurotransmitter amines, neurotransmitters were investigated in two patients with 3-PGDH deficiency. This revealed no abnormalities in the levels of g-aminobutyric acid, homovanillic acid and 5-hydroxyindole acetic acid [8] . The enzymatic diagnosis of 3-PGDH deficiency is confirmed by enzymatic assay of cultured skin fibroblasts [1]. 
Treatment and prognosis
Oral supplementation of the deficient amino acids proved to be very effective in the treatment of seizures [2]. Control of seizures was observed even when the patients were known to have had medically intractable seizures for many years. High dosages of amino acid are needed to obtain a persistent clinical response and biochemical normalization [2]. L-Serine is transported over the blood-brain barrier like all other neutral amino acids, i.e. by the neutral amino acid transporter. The affinity of this transporter for L-serine is relatively low and therefore L-serine has to compete with other neutral amino acids such as threonine [9] . High plasma L-serine concentrations will therefore facilitate transport over the blood-brain barrier. Treatment should start with L-serine at 400-600 mg/kg/day in four to six doses; most patients use a dose of L-serine of around 600 mg/ kg/day. If seizures are not controlled, glycine can be added to the treatment at a dose of 200-300 mg/kg/day [2] . With the amino acid therapy, a clinical response with regard to the seizures is to be expected within 1-2 weeks after the initiation of treatment. However, the electroencephalogram abnormalities can persist for some months after the clinically manifest seizures have stopped [2]. The biochemical abnormalities normalize during treatment with amino acids, although in some patients serine levels remain just below the normal range. The amino acids in the dose recommended above were well tolerated and have had few side-effects [10] . One patient started complaining of having vomiting, nystagmus and myoclonic jerks 1 week after the introduction of L-serine at 500 mg/kg/day (T. J. At present, it is not clear what the safe upper limit of Lserine dosage might be. Hausler et al.
[3] reported alterations in CSF amino acid concentrations in two patients with 3-PGDH deficiency when L-serine was given at a dose of 650 mg/kg/day or more in combination with glycine (40-85 mg/kg/day). These authors also reported adverse effects of very high doses of amino acids when L-serine combined with glycine was given at doses of 1400 mg/kg/day and 85 mg/kg/day, respectively. At present, L-serine at a dose of 600 mg/kg/day therefore seems a reasonable upper limit for amino acid therapy, but long-term monitoring of treated patients is required before a more definitive safe upper limit can be established.
Long-term follow-up of patients on amino acid therapy demonstrated that not all remained free of seizures. Furthermore, in those patients treated relatively late, i.e. after their first year of life, little or no progress in psychomotor development was observed during treatment [10] . Interestingly, upon follow-up there was a marked increase in the white-matter volume in MRI, and, in some patients, progression of myelination was observed during treatment [7] .
It seems obvious that early treatment would have improved the patients' prognosis with regard to their psychomotor development. Ultimately, we showed this in a girl diagnosed prenatally and in whom L-serine therapy was given to the mother at 27 weeks of gestation because of a decelerating growth of the fetal head circumference. With this maternal L-serine therapy a normalization of fetal head growth was demonstrated by using fetal ultrasound, and she was born normocephalic. Treatment was continued on the second day of life, and now -aged 3 years -the girl demonstrates normal psychomotor development (T. J. de Koning, L. W. J. Genetics 3-PGDH deficiency is an autosomal recessive disorder and the 3-PGDH gene is located on chromosome 1q12. Recently, genetic defects were identified in patients with 3-PGDH deficiency, and so far only missense mutations of the gene encoding the C-terminal part of the protein have been identified by Klomp et al. [11] . Their paper represents the first report on the molecular characterization of 3-PGDH deficiency. Two different homozygous missense mutations were described in six patients. Both mutations lead to a significant reduction of enzyme activity after expression of the mutant enzymes in vitro. This characterization of the genetic defect of 3-PGDH deficiency definitively established 3-PGDH deficiency as a serine-synthesis deficiency disorder and provided the molecular tools for family diagnosis and further research. Expression studies of these mutations as well as expression of a mutant protein lacking the last 209 amino acids of the C-terminal region demonstrated considerable residual enzyme activity -a finding similar to the data on 3-PGDH residual activity in patient fibroblasts [5 . , 11, 12] . These data suggest that the mutations observed in patients to date have been relatively mild mutations, and one can speculate that mutant proteins with less residual activity are not compatible with life. Prenatal diagnosis is possible by mutation analysis only and not by enzymatic assay, because of a lack of data on enzyme activity in chorionic villi and amniocytes.
3-Phosphoserine phosphatase deficiency
The second disorder of serine biosynthesis, 3-PSP deficiency, has been reported only in a single casereport [13] . This patient -a boy who also suffered from Williams-Beuren syndrome -was found to have low CSF serine, albeit less pronounced than that usually observed in 3-PGDH deficiency. A deficiency of PSP activity was detected in cultured skin fibroblasts. This boy was also treated with L-serine: a favorable response, most notably an increase in head circumference, was reported. Unfortunately, the patient was lost to follow-up and there are no data on the long-term effects of the therapy. There has been no confirmation of the defect by molecular genetics in this patient. To date, no other patients with 3-PSP deficiency have been reported; nor has 3-PSP deficiency been detected in other patients with Williams-Beuren syndrome.
Other disease states associated with alterations in serine metabolism
Serine deficiency of unknown cause has been reported in another single case-report of a girl with a progressive polyneuropathy, ichthyosis, growth retardation and delayed puberty [14] . No deficiency in any of the three L-serine biosynthetic enzymes was detected and the basic defect remains to be resolved. Nevertheless, treatment with L-serine resulted in a clear and sustained improvement in muscle strength and ichthyosis. More patients, some of which are adults, are known to us who also presented with polyneuropathy, mental retardation and deficient levels of serine levels in CSF. No deficiency in the serine biosynthetic enzymes could be demonstrated.
In contrast to the serine-deficiency disorders discussed above, elevated levels of serine and glycine have been associated in some studies with psychiatric disease, especially schizophrenia. It was hypothesized that the elevated amino acid concentrations would influence functioning of the N-methyl-D-aspartate (NMDA)-receptor complex [15, 16] . However, these findings of abnormal concentrations of serine and glycine in subjects with psychiatric disorders were not confirmed by other studies [17, 18] . Indeed, an alternative hypothesis for the biological origin of schizophrenia, and also relating to Lserine pathways, suggests exactly the opposite, namely hypofunction of excitatory amino acids and insufficient NMDA-receptor activation [19] . Clinical evidence for the latter theory was obtained by the observations that stimulation of NMDA receptors by the administration of glycine, D-serine or D-cycloserine was beneficial to some patients with schizophrenia [20] [21] [22] [23] . More recent data on a large series of patients have demonstrated a genetic association between schizophrenia and D-amino acid oxidase, suggesting that a D-amino acid, probably Dserine, plays a role in the pathogenesis of schizophrenia [24 . . ]. To date, only plasma D-serine has been investigated in patients with schizophrenia. Hashimoto et al. [25] found that plasma D-serine concentrations were lower in a group of patients with schizophrenia.
Although the results of this study also favor the hypothesis that D-serine and NMDA-receptor (under)stimulation are involved in schizophrenia, it is doubtful whether plasma D-serine concentrations actually reflect D-serine concentrations in the brain, given the role of the kidney in the metabolism of D-serine [26] .
In any event, the psychiatric disorders for which serine and glycine metabolism have been investigated are likely to be heterogeneous in their pathogenesis. To gain more insight into the causative role of the amino acids of L-serine catabolic pathways in psychiatric disease, detailed information on the regulation of the pathways involved and the specific activities of particular enzymes, and a better understanding of the biological functions of D-serine and glycine are essential. Analysis of single-nucleotide polymorphisms, such as that performed by Chumakov et al. [24 . . ], in combination with metabolic profiling of patients with psychiatric disease is likely to prove most helpful in revealing the causes of the metabolic aberrations in psychiatric disease.
Roles of the serine-synthesis pathway in the central nervous system
The serious neurological symptoms observed in patients when serine is deficient indicate an important role of the L-serine biosynthetic and L-serine catabolic pathways in normal brain development and function. Given the fact that 3-PGDH deficiency is a defect in a biosynthetic pathway and that apparently no metabolites accumulate, we can assume that the symptoms are due to a lack of Lserine itself or of one of the L-serine-derived metabolites. This is consistent with the amelioration of symptoms after L-serine supplementation.
L-Serine plays an important role in multiple cellular reactions [27] . With regard to the neurological symptoms, we think the following functions of L-serine probably relate to the clinical phenotype: L-serine is a precursor for nucleotide synthesis necessary for cell proliferation; L-serine is a precursor for phospholipid synthesis; and Lserine is the precursor for the synthesis of glycine and Dserine.
L-Serine during development of the central nervous system
The presence of the serine biosynthetic pathway in brain tissue was established a long time ago [28] . 3-PGDH is highly expressed in fetal tissues, including brain tissue [11] . Data from in-situ hybridisation of 3-PGDH during development of the central nervous system showed a very strong expression of 3-PGDH mRNA during early fetal development, especially in the ventricular and subventricular zone of the fetal brain (T. Klomp et al. [11] , severe mutations in the 3-PGDH gene would probably not be compatible with life, because in patients with 3-PGDH deficiency only relatively mild mutations were found, resulting in considerable residual enzyme activity. The small brains in the 3-PGDH knock-out mouse were most likely caused by diminished proliferation of neuronal-glial precursor cells in the ventricular zone [30 . . ].
An impairment of neuronal-glial proliferation has been associated with insufficient brain growth or microcephaly in humans as well. Radial micro brain, which might be considered as the most extreme form of microcephaly, is likely to result from an impairment of neuronal precursor cell multiplication in early gestation, i.e. before 5-7 weeks [31] . The clinical features of patients with 3-PGDH deficiency are not as severe as those observed in radial micro brain, but are compatible with a milder reduction in brain volume such as that observed in microcephalia vera. Microcephalia vera is heterogeneous in its aetiology, but in many cases it is assumed that an impairment of neuronal proliferation before 20 weeks of gestation is involved [32] [33] [34] . In some cases of microcephalia vera, a depletion of cells in the germinative layer was observed, suggestive of exhaustion of neuronal proliferation [31] . In the 3-PGDH knock-out mouse reduced proliferation of stem cells in the ventricular zone or gernimative layer was also present [30 . . ]. In our opinion the microcephaly observed in 3-PGDH is not only explained by impaired proliferation of neuronalglial precursor cells. Other factors such as excessive cell death and impaired differentiation of neuronal processes will likely contribute to the microcephaly [31] . In-vitro studies have shown that a lack of L-serine results in impaired dendritogenesis and neuronal survival [35] [36] [37] . The observations in patients with 3-PGDH deficiency, namely that antenatal treatment of an affected fetus with L-serine from 27 weeks' gestation onwards resulted in a normalization of the fetal head circumference (T. J. de Koning, L. W. J. Klomp, A. C. C. van Oppen, F. A. Beemer, L. Dorland, I. E. T. van den Berg, R. Berger, unpublished observations) and that L-serine treatment in patients aged 10 months-7 years resulted in a markedly increased white-matter volume [7], cannot be explained by an impaired proliferation of precursor cells from the ventricular zone. Therefore, insufficient production of Lserine by glia at later developmental stages may be an additional factor leading to a reduction in brain volume in patients with 3-PGDH deficiency.
L-Serine and phospholipid synthesis
As already mentioned above, L-serine has trophic effects on neurons in culture, and affects dendritogenesis and the axon length of these cells [37] . These trophic effects on neurons in culture were also reported for L-serinederived phospholipids [36, 38, 39] . Mitoma et al. [38] and Furuya et al. [39] presented evidence consistent with a concentration-dependent role for ceramide in neuronal survival. A ceramide-related compound (C6-ceramide) promoted cell survival and neuritogenesis of immature hippocampal neurons and Purkinje cells at low concentrations, but resulted in neuronal cell death at higher concentrations. These results suggest a concentrationdependent and developmental stage-dependent role of the second messenger ceramide in cell-fate decisions in the neuronal cell-lineage. Furuya et al. [36] demonstrated that 3-PGDH is highly expressed in glia cells and that serine and glycine, synthesized in glia cells by the metabolic pathway defined by 3-PGDH, are essential neurotrophic factors. These amino acids are necessary for efficient survival, dendrite outgrowth and electrophysical development of Purkinje neurons in vitro. Impaired neuronal survival and increased apoptosis were observed in cerebellar Purkinje cells in culture when ceramide synthesis was inhibited. The enzymes of the L-serine biosynthetic pathway are restricted to glial cells and, most notably, astrocytes [29, 36, [40] [41] [42] . These cells clearly provide the microenvironment for optimal neuronal development and neuronal functioning and it is likely that L-serine homeostasis plays a pivotal role in maintaining this optimal microenvironment. Not only can astrocytes synthesize L-serine, but it is also likely that these cells release a significant amount of the L-serine synthesized to supply neurons with the necessary precursors for phospholipid synthesis. Neurons in culture use exogenous L-serine for the synthesis of L-serine-derived phospholipids. Mitoma et al. [43] have shown that the biosynthesis of these phospholipids is severely decreased when L-serine or glycine is absent. These authors showed that exogenous serine is required for the synthesis of phosphatidylserine, an important membrane phospholipid, in hippocampal neurons grown in the absence of astroglia. These results clearly demonstrate that astroglia-derived serine is necessary for neuronal lipid synthesis. In the absence of serine, a previously uncharacterized phospholipid, phosphatidylthreonine, is synthesized by these cells. The significance of this latter finding needs to be demonstrated further.
L-Serine-derived phospholipids include phosphoglycerides such as phosphatidylserine and phosphatidylcholine, and also complex macromolecules such as sphingolipids and glycolipids. One of the precursors of the latter is sphingosine, which is formed from Lserine and palmitoyl-coenzyme A and can be converted to ceramide, necessary for sphingomyelin and gangliosides. These L-serine-derived phospholipids are not only constituents of myelin, but also lipid messenger molecules involved in cellular differentiation, proliferation and the apoptosis-signalling pathway [44, 45] .
One can hypothesize that insufficient synthesis of phospholipids in 3-PGDH deficiency is also related to the reduced brain volume and the attenuated white matter in MRI. Some evidence for alterations in phospholipid composition were found by analyzing phospholipids in CSF from two patients with 3-PGDH deficiency, but these preliminary results certainly need further study [46] .
L-Serine and glycine and D-serine synthesis
Recently, Wolosker et al. [47] demonstrated the presence of DL-serine racemase in brain tissue, thereby linking the formation of two important neurotransmitters, glycine and D-serine, to L-serine catabolism (Fig. 1 ). Pursuant to their initial cloning of serine racemase [42] , these workers have now characterized serine racemase purified from rat brain. The results reveal that serine racemase is a 37 kDa protein, which requires pyridoxal 5' phosphate and is highly selective for L-serine. These authors also demonstrated that serine racemase is a glial enzyme and so the metabolism of D-serine appears to be very similar to glutamate; it is restricted to glial cells and astrocytes in particular. A model of how astrocytes and neurons interact with regard to glutamate and D-serine has been proposed by Snyder and Kim [48] . They suggested that glutamate not only binds to the NMDAreceptor complex, but also triggers the release of Dserine from nearby astrocytes via activation of non-NMDA receptors. Subsequently, both glutamate and Dserine will activate the post-synaptic NMDA-receptor complex.
The role of glycine in neurotransmission has been known for a long time. It is the major inhibitory neurotransmitter in the spinal cord and brain stem and its functions include the regulation of locomotor behavior [49] . Recently, a role for glycine and glycine receptors during fetal brain development has also been demonstrated [49] . Disorders involving defects in glycine catabolism (glycine encephalopathy) or glycine receptors (hyperekplexia) are wellknown neurological disorders [50, 51] . This is not the case for D-serine, for which a role in human disease has not been established. Although both glycine and D-serine are obligatory co-agonists of the NMDA-receptor complex they must have different functions. Considerable regional differences in the levels of glycine and D-serine and different developmental 'profiles' in postnatal rodent brain were demonstrated for glycine and D-serine [52, 53] . For instance, D-serine co-localized with the NR2A/B NMDA-receptor subtype in distinctive areas of the brain; in most brain areas with a high immunoreactivity for Dserine a low immunoreactivity for glycine is observed and vice versa. In a comprehensive descriptive study [52] describing comparative cellular localizations of D-serine, glycine and NMDA receptors in rat cerebellum, designed to explore the possibility that glycine and D-serine are endogenous ligands for these receptors, D-serine concentrations were found to be high at birth and decline with age, whereas glycine concentrations rose with age and in the adult cerebellum glycine appeared to be the main neurotransmitter. The results are consistent with a predominant role for D-serine as an NMDA-receptor coactivator in the telencephalon and developing brain, whereas glycine is more predominantly detected in adult cerebellum and hindbrain. The significance of these findings requires further investigation.
It seems likely that a reduction in D-serine relates to some of the symptoms observed in 3-PGDH deficiency, but, to date, D-serine concentrations have not been analyzed in this disorder and the relationship remains to be established.
Conclusion
Serine-deficiency disorders comprise a new group of inborn errors of metabolism with severe neurological symptoms. Although not many patients have been reported to date and the disorders are probably rare, recognition of the clinical phenotype is important because serine-deficiency disorders are potentially treatable. Therefore, they should be included in the differential diagnosis of patients with congenital microcephaly and intractable seizures or early onset of psychomotor retardation. Plasma amino acid analysis after an overnight fast can be used as a first diagnostic test, but CSF amino acid analysis is the diagnostic method of choice. Treatment consists of oral replacement therapy with high dosages of L-serine; in some patients glycine has to be added to the treatment. Moreover, serine-deficiency disorders can provide important models for the study of the role of L-serine and L-serine-derived molecules in brain development and function.
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